1. Home
  2. TIGR vs GYRE Comparison

TIGR vs GYRE Comparison

Compare TIGR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UP Fintech Holding Ltd representing fifteen

TIGR

UP Fintech Holding Ltd representing fifteen

HOLD

Current Price

$6.10

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.82

Market Cap

759.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIGR
GYRE
Founded
2014
2002
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
759.1M
IPO Year
2018
2004

Fundamental Metrics

Financial Performance
Metric
TIGR
GYRE
Price
$6.10
$6.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$14.20
$17.00
AVG Volume (30 Days)
2.3M
129.2K
Earning Date
03-19-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
N/A
$275,000.00
Revenue This Year
$15.74
$19.88
Revenue Next Year
$13.91
N/A
P/E Ratio
$9.77
$352.00
Revenue Growth
N/A
N/A
52 Week Low
$6.15
$6.11
52 Week High
$13.55
$11.77

Technical Indicators

Market Signals
Indicator
TIGR
GYRE
Relative Strength Index (RSI) 27.50 38.73
Support Level N/A N/A
Resistance Level $8.77 $8.25
Average True Range (ATR) 0.27 0.40
MACD -0.08 -0.07
Stochastic Oscillator 2.23 11.98

Price Performance

Historical Comparison
TIGR
GYRE

About TIGR UP Fintech Holding Ltd representing fifteen

UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: